Edwards Lifesciences (EW) is trading up at $88.10 (+1.91%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on EW
One firm's current price target on Edwards Lifesciences: $104 — 18% above the current $88.1. Each is tracked to its date and scored the same way a member's call is.
- TD Cowen $84.5 → $104 by Jul 2027 Jul 21, 2026 via Investing.com · TD Cowen's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Edwards Lifesciences revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.96B | $3.44B | $3.72B | $4.35B | $4.39B | $5.23B | $4.46B | $5.01B | $5.44B | $6.07B |
| Growth (year over year) | +18.8% | +15.9% | +8.4% | +16.8% | +0.9% | +19.3% | −14.7% | +12.2% | +8.6% | +11.5% |
| Gross profit | $2.17B | $2.56B | $2.78B | $3.23B | $3.31B | $3.98B | $3.74B | $4.03B | $4.32B | $4.73B |
| Gross margin | 73.1% | 74.5% | 74.8% | 74.4% | 75.4% | 76.1% | 83.8% | 80.5% | 79.5% | 78.0% |
| Operating income | $751.2M | $1.09B | $748.2M | $1.15B | $897.6M | $1.69B | $1.50B | $1.31B | $1.38B | $1.26B |
| Operating margin | 25.3% | 31.7% | 20.1% | 26.4% | 20.5% | 32.3% | 33.6% | 26.1% | 25.3% | 20.8% |
| Net income | $569.5M | $583.6M | $722.2M | $1.05B | $823.4M | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| Net margin | 19.2% | 17.0% | 19.4% | 24.1% | 18.8% | 28.7% | 34.1% | 28.0% | 76.7% | 17.7% |
| EPS (diluted) | $0.87 | $0.90 | $1.13 | $1.64 | $1.30 | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Balance sheet | ||||||||||
| Cash and equivalents | $930.1M | $818.3M | $714.1M | $1.18B | $1.18B | $862.8M | $769.0M | $1.13B | $3.05B | $2.94B |
| Total assets | $4.51B | $5.67B | $5.32B | $6.49B | $7.24B | $8.50B | $8.29B | $9.36B | $13.1B | $13.7B |
| Total liabilities | $1.89B | $2.71B | $2.18B | $2.34B | $2.66B | $2.67B | $2.49B | $2.64B | $2.99B | $3.36B |
| Long-term debt | $822.3M | $438.4M | $593.8M | $594.4M | $595.0M | $595.7M | $596.3M | $597.0M | $597.7M | $598.3M |
| Shareholders' equity | $2.62B | $2.96B | $3.14B | $4.15B | $4.57B | $5.84B | $5.81B | $6.65B | $10.00B | $10.3B |
| Cash flow | ||||||||||
| Operating cash flow | $704.4M | $1.00B | $926.7M | $1.18B | $1.05B | $1.73B | $1.22B | $895.8M | $542.3M | $1.60B |
| Capital expenditure | $176.1M | $168.1M | $238.7M | $254.4M | $407.0M | $325.8M | $244.6M | $253.0M | $252.4M | $260.2M |
| Free cash flow | $528.3M | $832.6M | $688.0M | $928.5M | $647.3M | $1.41B | $973.6M | $642.8M | $289.9M | $1.33B |
| Share buybacks | $662.3M | $763.3M | $795.5M | $263.3M | $625.4M | $512.8M | $1.73B | $879.6M | $1.16B | $893.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B | $1.74B |
| Growth (year over year) | +8.9% | +9.4% | +6.2% | +11.9% | +14.7% | +13.3% | +16.7% | +13.6% |
| Gross profit | $1.09B | $1.09B | $1.11B | $1.19B | $1.21B | $1.23B | $1.29B | $1.35B |
| Gross margin | 80.6% | 78.9% | 78.7% | 77.5% | 77.8% | 78.1% | 78.0% | 77.5% |
| Operating income | $350.6M | $312.6M | $394.8M | $411.2M | $307.1M | $151.1M | $477.6M | $513.2M |
| Operating margin | 25.9% | 22.6% | 27.9% | 26.8% | 19.8% | 9.6% | 29.0% | 29.5% |
| Net income | $3.07B | $385.6M | $358.0M | $333.2M | $291.1M | $91.2M | $380.7M | $241.9M |
| Net margin | 226.7% | 27.8% | 25.3% | 21.7% | 18.7% | 5.8% | 23.1% | 13.9% |
| EPS (diluted) | $5.13 | $0.65 | $0.61 | $0.56 | $0.50 | $0.16 | $0.66 | $0.42 |
| Balance sheet | ||||||||
| Cash and equivalents | $3.68B | $3.05B | $3.14B | $3.27B | $2.69B | $2.94B | $2.45B | $2.91B |
| Total assets | $13.0B | $13.1B | $13.0B | $13.5B | $13.3B | $13.7B | $13.3B | $13.9B |
| Total liabilities | $3.36B | $2.99B | $2.83B | $2.88B | $3.07B | $3.36B | $2.99B | $3.14B |
| Long-term debt | $597.5M | $597.7M | $597.8M | $598.0M | $598.2M | $598.3M | $598.5M | $598.7M |
| Shareholders' equity | $9.55B | $10.00B | $10.1B | $10.5B | $10.2B | $10.3B | $10.3B | $10.6B |
| Cash flow | ||||||||
| Operating cash flow | $351.8M | −$127.5M | $280.4M | $290.2M | $573.7M | $450.9M | $43.8M | $651.9M |
| Capital expenditure | $51.9M | $49.8M | $56.0M | $49.3M | $57.5M | $97.4M | $64.9M | $66.9M |
| Free cash flow | $299.9M | −$177.3M | $224.4M | $240.9M | $516.2M | $353.5M | −$21.1M | $585.0M |
| Share buybacks | $901.0M | $100.1M | $258.6M | $5.50M | $588.7M | $40.6M | $421.8M | $153.3M |
From Edwards Lifesciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Edwards Lifesciences
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
Source: Wikipedia — Edwards Lifesciences
- Headquarters
- Irvine, California From SEC filings, Oct 2026
Recent News (19)
-
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock
-
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
-
Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth
Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth
-
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock
-
Is Edwards Lifesciences Stock Underperforming the Dow?
Is Edwards Lifesciences Stock Underperforming the Dow?
-
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible…
-
Edwards Lifesciences SVP sells $49,533 in stock
Edwards Lifesciences SVP sells $49,533 in stock
-
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
-
Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom
Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom
-
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?
-
Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match
-
Form 4 Edwards Lifesciences Corp For: 30 July Form 4 Edwards Lifesciences Corp For: 30 July
-
Form 4 Edwards Lifesciences Corp For: 27 July Form 4 Edwards Lifesciences Corp For: 27 July
-
-
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion? Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion?
-
Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary
-
Edwards Lifesciences Q2 Earnings Call Highlights Edwards Lifesciences Q2 Earnings Call Highlights
-
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth
-
More Health Care stocks
- DHR Danaher Corporation
- DVA DaVita
- DXCM Dexcom
- ELV Elevance Health
- GEHC GE HealthCare
- GILD Gilead Sciences
- HCA HCA Healthcare
- HSIC Henry Schein